Literature DB >> 27995575

Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda.

Ned Sacktor1, David R Boulware2, Mahsa Abassi2,3, Bozena M Morawski2,3, Gertrude Nakigozi4, Noeline Nakasujja3,5, Xiangrong Kong6, David B Meya2,3,5, Kevin Robertson7, Ronald Gray6, Maria J Wawer6.   

Abstract

In the USA, increased cerebrospinal fluid (CSF) inflammatory cytokines have been observed in antiretroviral therapy (ART)-naive, HIV-seropositive individuals with HIV-associated neurocognitive disorder (HAND). We characterized the relationship between HAND and CSF biomarker expression in ART-naive, HIV-seropositive individuals in Rakai, Uganda. We analyzed CSF of 78 HIV-seropositive, ART-naive Ugandan adults for 17 cytokines and 20 neurodegenerative biomarkers via Luminex multiplex assay. These adults underwent neurocognitive assessment to determine their degree of HAND. We compared biomarker concentrations between high and low CD4 groups and across HAND classifications, adjusting for multiple comparisons. Individuals with CD4 <200 cells/μL (N = 38) had elevated levels of CSF Interleukin (IL)-2, IL-12, granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-α, matrix metalloproteinase (MMP)-1, MMP-7, and S100 calcium-binding protein B (S100B) and lower levels of amyloid β42. Individuals with CD4 351-500 cells/μL (N = 40) had significantly higher CSF levels of interleukin (IL)-1β, amyloid β42, and soluble receptor for advanced glycation end products (sRAGE). Increasing levels of S100B, platelet-derived growth factor-AA (PDGF-AA), brain-derived neurotrophic factor (BDNF), and sRAGE were associated with decreased odds of mild neurocognitive disorder (n = 22) or HIV-associated dementia (n = 15) compared with normal function (n = 30) or asymptomatic neurocognitive impairment (n = 11). Increased levels of interferon (IFN)-γ were associated with increased odds of mild neurocognitive impairment or HIV-associated dementia relative to normal or asymptomatic neurocognitive impairment. Proinflammatory CSF cytokines, chemokines, and neurodegenerative biomarkers were present in increasing concentrations with advanced immunosuppression and may play a role in the development of HAND. The presence of select CNS biomarkers may also play a protective role in the development of HAND.

Entities:  

Keywords:  Cytokine expression; Dementia; HIV-associated neurocognitive disorders; Inflammation; Neurodegenerative biomarkers

Mesh:

Substances:

Year:  2016        PMID: 27995575      PMCID: PMC5441942          DOI: 10.1007/s13365-016-0505-9

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  27 in total

1.  CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.

Authors:  B J Brew; L Pemberton; K Blennow; A Wallin; L Hagberg
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

2.  Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

Authors:  Enzo Emanuele; Angela D'Angelo; Carmine Tomaino; Giuliano Binetti; Roberta Ghidoni; Pierluigi Politi; Livia Bernardi; Raffaele Maletta; Amalia C Bruni; Diego Geroldi
Journal:  Arch Neurol       Date:  2005-11

3.  Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease.

Authors:  E R Peskind; W S Griffin; K T Akama; M A Raskind; L J Van Eldik
Journal:  Neurochem Int       Date:  2001 Nov-Dec       Impact factor: 3.921

4.  Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia.

Authors:  K Conant; J C McArthur; D E Griffin; L Sjulson; L M Wahl; D N Irani
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

5.  The International HIV Dementia Scale: a new rapid screening test for HIV dementia.

Authors:  Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

6.  Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients.

Authors:  Douglas A Green; Eliezer Masliah; Harry V Vinters; Pouneh Beizai; David J Moore; Cristian L Achim
Journal:  AIDS       Date:  2005-03-04       Impact factor: 4.177

7.  Early penetration of the blood-brain-barrier by HIV.

Authors:  L Resnick; J R Berger; P Shapshak; W W Tourtellotte
Journal:  Neurology       Date:  1988-01       Impact factor: 9.910

8.  Interleukin-6 and granulocyte macrophage-CSF in the cerebrospinal fluid from HIV infected subjects with involvement of the central nervous system.

Authors:  O Perrella; M Guerriero; E Izzo; M Soscia; P B Carrieri
Journal:  Arq Neuropsiquiatr       Date:  1992-06       Impact factor: 1.420

Review 9.  Yin and Yang of PDGF-mediated signaling pathway in the context of HIV infection and drug abuse.

Authors:  Honghong Yao; Crystal Bethel-Brown; Fang Niu; Lu Yang; Fuwang Peng; Shilpa Buch
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-20       Impact factor: 4.147

Review 10.  Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND).

Authors:  Vasudev R Rao; Arthur P Ruiz; Vinayaka R Prasad
Journal:  AIDS Res Ther       Date:  2014-05-19       Impact factor: 2.250

View more
  30 in total

1.  S100B and its association with HIV-associated neurocognitive disorders.

Authors:  Nath Limpruttidham; Brooks I Mitchell; Kalpana J Kallianpur; Beau K Nakamoto; Scott A Souza; Bruce Shiramizu; Lishomwa C Ndhlovu; Dominic C Chow; Cecilia M Shikuma
Journal:  J Neurovirol       Date:  2019-07-05       Impact factor: 2.643

2.  Letter to the Editor.

Authors:  Mahsa Abassi; Ned Sacktor
Journal:  J Neurovirol       Date:  2019-07-05       Impact factor: 2.643

3.  Expression profiling suggests microglial impairment in human immunodeficiency virus neuropathogenesis.

Authors:  Stephen D Ginsberg; Melissa J Alldred; Satya M Gunnam; Consuelo Schiroli; Sang Han Lee; Susan Morgello; Tracy Fischer
Journal:  Ann Neurol       Date:  2018-02-10       Impact factor: 10.422

4.  HIV-1 Tat promotes astrocytic release of CCL2 through MMP/PAR-1 signaling.

Authors:  P Lorenzo Bozzelli; Tao Yin; Valeria Avdoshina; Italo Mocchetti; Katherine E Conant; Kathleen A Maguire-Zeiss
Journal:  Glia       Date:  2019-05-23       Impact factor: 7.452

5.  Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.

Authors:  Carissa D Winland; Nora Welsh; Alberto Sepulveda-Rodriguez; Stefano Vicini; Kathleen A Maguire-Zeiss
Journal:  Eur J Neurosci       Date:  2017-10-10       Impact factor: 3.386

6.  Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.

Authors:  Leah H Rubin; Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Sarah M Lofgren; David R Boulware; Raha Dastgheyb; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Ned Sacktor
Journal:  J Neurovirol       Date:  2019-06-19       Impact factor: 2.643

7.  HIV-1 gp120 Upregulates Brain-Derived Neurotrophic Factor (BDNF) Expression in BV2 Cells via the Wnt/β-Catenin Signaling Pathway.

Authors:  Yongdi Wang; Jinxu Liao; Shao-Jun Tang; Jianhong Shu; Wenping Zhang
Journal:  J Mol Neurosci       Date:  2017-05-30       Impact factor: 3.444

8.  The Association of Immune Markers with Cognitive Performance in South African HIV-Positive Patients.

Authors:  Monray E Williams; Jonathan C Ipser; Dan J Stein; John A Joska; Petrus J W Naudé
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-06       Impact factor: 4.147

Review 9.  Understanding the Role of Antiviral Cytokines and Chemokines on Neural Stem/Progenitor Cell Activity and Survival.

Authors:  Manisha N Chandwani; Patrick S Creisher; Lauren A O'Donnell
Journal:  Viral Immunol       Date:  2018-10-10       Impact factor: 2.257

10.  A neuropathologic diagnosis of Alzheimer's disease in an older adult with HIV-associated neurocognitive disorder.

Authors:  Joanna Hellmuth; Benedetta Milanini; Eliezer Masliah; Maria Carmela Tartaglia; Miranda B Dunlop; David J Moore; Shireen Javandel; Saskia DeVaughn; Victor Valcour
Journal:  Neurocase       Date:  2018-10-10       Impact factor: 0.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.